Mississippi Nurse Denied Drug Prescribing Privileges by DEA
Published Date: 9/30/2025
Notice
Summary
Jody Adams, a nurse practitioner from Mississippi, tried to get a DEA registration but got denied because she issued three controlled substance prescriptions without proper authorization. This decision means she can’t legally prescribe these drugs, protecting public safety. The denial is final, and no hearing was requested, so the decision is effective immediately with no money penalties mentioned.
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
DEA Registration Denied for Jody Adams
The Drug Enforcement Administration denied the DEA registration application (Control No. W24008696M) of Jody Adams, N.P., and also denied any other pending registration application of hers in Mississippi. The record shows she admitted issuing three controlled-substance prescriptions without an active DEA registration between January 18, 2023 and January 29, 2024 (two prescriptions for testosterone, a Schedule III drug, and one for pregabalin, a Schedule V drug). The denial is effective October 30, 2025.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
2026-10090 — Exempt Chemical Preparations Under the Controlled Substances Act
The Drug Enforcement Administration (DEA) reviewed and decided on applications for special chemical mixtures that don’t fall under strict drug rules, covering requests from July 2025 to March 2026. Some mixtures got approved, others denied, and a few listings were fixed from earlier notices. If you’re involved with these chemicals, you’ve got until July 20, 2026, to share your thoughts—no fees or big costs involved, just your voice!
2026-09566 — Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
Starting May 13, 2026, the DEA officially puts CUMYL-PEGACLONE—a chemical that can be risky—into Schedule I, the strictest drug category. This means anyone making, selling, or using it now faces tough rules and penalties. This move helps the U.S. follow international drug laws and keeps communities safer without any new fees or costs.
2026-08588 — Bulk Manufacturer of Controlled Substances Application: Patheon API Inc.
Patheon API Inc. wants to make large amounts of special research drugs like dimethyltryptamine and psilocybin. This affects researchers and companies involved in clinical trials, with a chance to comment or ask for a hearing by July 6, 2026. No money changes are mentioned, but this move could speed up important medical studies.
Previous / Next Documents
Previous: 2025-19061 — Self-Regulatory Organizations; NYSE Arca, Inc.; Notice of Filing and Immediate Effectiveness of Proposed Rule Change Relating to the Listing and Trading of Shares of the 7RCC Spot Bitcoin and Carbon Credit Futures ETF
NYSE Arca is switching how the 7RCC Spot Bitcoin and Carbon Credit Futures ETF shares are listed and traded, moving from a special rule to a more general one. This change affects investors trading these shares and takes effect immediately, aiming to make trading smoother and more flexible. No new fees or costs are introduced, but the update could impact how quickly and easily shares are bought and sold.
Next: 2025-19064 — Self-Regulatory Organizations; National Securities Clearing Corporation; Notice of Filing and Immediate Effectiveness of Proposed Rule Change To Amend NSCC Rule 22 (Suspension of Rules)
The National Securities Clearing Corporation (NSCC) just updated its Rule 22, which lets them pause certain rules when needed. This change affects NSCC and its sister agencies, helping them act faster and smarter during unusual situations. The update is already in effect, so members should be ready for quicker decisions that could impact how money moves in the market.